The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase I study of trispecific anti-CD20xCD19xCD22 CAR T-cells for R/R B-cell malignancies
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a Phase I study of a trispecific anti-CD20xCD19xCD22 CAR T-cell product for relapsed/refractory (R/R) B-cell malignancies. Despite promising preclinical data, the product did not show meaningful efficacy in human patients, with a lack of robust engraftment. Dr Shah emphasizes that even negative data can be valuable for informing future research and the development of novel CAR-T strategies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
